Comparison of two infusion rates of antithrombin concentrate in cardiopulmonary bypass surgery

Perfusion

Volumn 25, Issue 5, 2010, Pages 305-312

  Lund, Philip E ^a   Wassbäck, Göran ^a   Thomas, Owain ^b   Carlsson, Tony ^a   Schött, Ulf ^c  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Anticoagulation; Antithrombin; Cardiac surgery; Cardiopulmonary bypass; Heparin resistance

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; ANTITHROMBIN III CONCENTRATE; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; HEPARIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ANAPHYLAXIS; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; ELECTIVE SURGERY; FEMALE; HEART SURGERY; HEART VALVE SURGERY; HEMODYNAMICS; HEPARINIZATION; HUMAN; INFUSION RATE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; KINETICS; LUNG FUNCTION TEST; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; ANTITHROMBINS; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HEMODYNAMICS; HEMORRHAGE; HEPARIN; HUMANS; KINETICS; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS;

EID: 79952198753     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/0267659110377677     Document Type: Article

References (28)

1. Spiess BD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg 2008; 85:2153-2160. (Pubitemid 351685591)
2. Lemmer JH Jr, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002; 123: 213-217. (Pubitemid 34127106)
3. Avidan MS, Levy JH, van Aken H, et al. Recombinanthuman antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130: 107-113. (Pubitemid 40941676)
4. Despotis G, Eby C, Lublin DM. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion 2008; 48(1 Suppl): 2-30.
5. Rodríguez-López JM, del Barrio E, Lozano FS, Muriel C. Does preoperative level of antithrombin III predict heparin resistance during extracorporeal circulation? Anesth Analg 2008; 107: 1444-1445.
6. Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000; 70: 873-877.
7. Warren BL, Eid A, Singer P, et al; KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-1878. (Pubitemid 33010239)
8. Chan T, Hwang NC, Lim CH. A statistical analysis of factors predisposing patients to heparin resistance. Perfusion 2006; 21: 99-103.
9. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1994; 58: 799-804. (Pubitemid 24319632)
10. Cohen JR, Tenenbaum N, Sarfati I, et al. In vivo inactivation of antithrombin III is promoted by heparin during cardiopulmonary bypass. J Invest Surg 1992; 5: 45-49.
11. Avidan MS, Levy JH, Scholz J, et al. A phase III, double-blind, placebo-controlled, multicenter study on theefficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005; 102: 276-284. (Pubitemid 40189074)
12. Shore-Lesserson L, Manspeizer HE, Bolastig M, Harrington D, Vela-Cantos F, DePerio M. Anticoagulation for cardiac surgery in patients receiving preoperative heparin: use of the high-dose thrombin time. Anesth Analg 2000; 90: 813-818. (Pubitemid 30190783)
13. Nicholson SC, Keeling DM, Sinclair ME, Evans RD. Heparin pretreatment does not alter heparin requirements during cardiopulmonary bypass. Br J Anaesth 2001; 87: 844-847. (Pubitemid 33130273)
14. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time. Perfusion 2003; 18: 269-276. (Pubitemid 37369281)
15. Kim YS, Murkin JM, Adams SJ. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery. Heart Surg Forum 2004; 7: 599-604.
16. Garvin S, Fitzgerald DC, Despotis G, Shekar P, Body SC. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg 2009 [Epub ahead of print]
17. Garvin S, Fitzgerald D, Muehlschlegel JD, et al. Heparin dose response is independent of perioperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations. Anesth Analg 2010 [Epub ahead of print]
18. Staples MH, Dunton RF, Karlson KJ, Leonardi HK, Berger RL. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 1994; 57: 1211-1216. (Pubitemid 24204506)
19. Linden MD, Schneider M, Baker S, Erber WN. Decreased concentration of antithrombin after preoperative therapeutic heparin does not cause heparin resistance during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2004; 18: 131-135. (Pubitemid 38506855)
20. Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000; 90: 1076-1079. (Pubitemid 30253452)
21. Ekbäck G, Axelsson K, Ryttberg L, et al. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg 2000; 91:1124-1130.
22. Alwi I. The role of low-molecular-weight heparins inthe management of unstable angina and non-ST elevation myocardial infarction. Acta Med Indones 2008; 40: 228-232.
23. Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003; 41: 394-402. (Pubitemid 36164492)
24. Pleym H, Videm V, Wahba A, et al. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively. Eur J Cardiothorac Surg 2006; 29: 933-940. (Pubitemid 43728598)
25. Li Y, Rodriquez M, Spencer FA, Becker RC. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance. J Thromb Thrombolysis 2002; 14:123-129. (Pubitemid 36559678)
26. Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007; 67: 1429-1440. (Pubitemid 47026392)
27. Dietrich W, Spannagl M, Schramm W, Vogt W, Barankay A, Richter JA. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 102: 505-514.
28. Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol 2010; 149: 613-619. [Epub ahead of print]